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Summary Purpose TAK-733, an investigational, selective,
allosteric MEK1/2 inhibitor, has demonstrated antitumor effects
against multiple cancer cell lines and xenograft models. This
first-in-human study investigated TAK-733 in patients with solid
tumors. Methods Patients received oral TAK-733 once daily on
days 1–21 in 28-day treatment cycles. Adverse events (AEs)
were graded using the Common Terminology Criteria for AEs
version 3.0. Response was assessed using RECIST v1.1. Blood
samples for TAK-733 pharmacokinetics and pharmacodynamics
(inhibition of ERK phosphorylation) were collected during cycle
1. Results Fifty-one patients received TAK-733 0.2–22 mg.
Primary diagnoses included uveal melanoma (24 %), colon can-
cer (22 %), and cutaneous melanoma (10 %). Four patients had
dose-limiting toxicities of dermatitis acneiform, plus fatigue and
pustular rash in one patient, and stomatitis in one patient. The
maximum tolerated dose was 16 mg. Common drug-related AEs
included dermatitis acneiform (51 %), diarrhea (29 %), and in-
creased blood creatine phosphokinase (20 %); grade ≥ 3 AEs
were reported in 27 (53 %) patients. Median Tmax was 3 h; sys-
temic exposure increased less than dose-proportionally over the
dose range 0.2–22 mg. On day 21 maximum inhibition of ERK
phosphorylation in peripheral blood mononuclear cells of 46–
97 % was seen in patients receiving TAK-733 ≥ 8.4 mg.
Among 41 response-evaluable patients, 2 (5 %) patients with
cutaneous melanoma (one with BRAF L597R mutant melano-
ma) had partial responses.ConclusionsTAK-733 had a generally
manageable toxicity profile up to the maximum tolerated dose,
and showed the anticipated pharmacodynamic effect of sustained
inhibition of ERK phosphorylation. Limited antitumor activity
was demonstrated. Further investigation is not currently planned.
Keywords TAK-733 .MEKinhibition .Phase1 .Solidtumor
Introduction
The Ras/Raf/MEK/ERK mitogen-activated cascade plays a
central role in the signaling required for cell proliferation, sur-
vival, motility, differentiation, and angiogenesis [1].
Dysregulation or hyperactivation of this cascade is common
in many human cancers [1, 2]. In particular, MEK is frequently
activated in cancers with mutations in established upstream
oncogenes [3, 4]; specifically, mutations in RAS and RAF on-
cogenes can lead to increased MEK activation [3]. The RAS
gene family members include HRAS, KRAS, and NRAS, with
the latter two being the isoforms commonly mutated in cancers.
RAS activating mutations occur in 30 % of all cancers, includ-
ing a high prevalence in melanoma (15–25 %) [3, 5], with
KRAS mutations more common in adenocarcinomas and solid
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tumors and NRAS mutations more common in leukemia, thy-
roid carcinoma, and malignant melanoma [6]. RAS, specifically
KRAS [6], is frequently mutated in colorectal cancer (CRC) and
has been linked to CRC initiation and progression [7, 8].
Furthermore, approximately 8 % of human tumors have muta-
tions in BRAF (a member of the RAF family) — melanoma,
thyroid cancer, and CRC have been associated with a high
frequency of BRAF mutations [9, 10]. Specifically, the
V600E point mutation accounts for more than 80 % of BRAF
activating mutations [9, 10].
Therefore, given this background, MEK is a potential
therapeutic target of interest for pharmacologic interven-
tion in cancer. Inhibition of MEK has been shown to
impair cell proliferation and impact a diverse array of
cellular events including differentiation, apoptosis, and
angiogenesis [11–15]. A number of MEK1/2 inhibitors
are currently being investigated in the clinic across a
range of cancers [16–19] including gynecologic malig-
nancies [20], melanoma [17, 21], colorectal cancer [17],
and acute myelogenous leukemia [22], with trametinib
approved alone and in combination with the BRAF in-
hibitor dabrafenib for advanced metastatic melanoma
with BRAF V600 mutations [23].
TAK-733 is an investigational, orally available, selective,
non-ATP competitive, allosteric inhibitor of MEK1/2 with an
IC50 for MEK signaling inhibition of 2–5 nM [24]. In the pre-
clinical setting, TAK-733 has exhibited antitumor effects
in vitro and in vivo against multiple cancer cell lines and xeno-
graft models. For example, TAK-733 has demonstrated activity
against multiple cutaneous melanoma cell lines, with a high
proportion of BRAF V600E-mutant cell lines showing high
sensitivity (IC50 < 0.1 μM) and with no statistically significant
association between BRAF status and response [25], and
against uveal melanoma cell lines [26]. Additional studies have
also shown tumor growth inhibition and regressions with TAK-
733 (dosed once daily) in human melanoma explant mouse
models and mouse xenograft models [25, 27]. Synergistic ac-
tivity was seen with TAK-733 in combination with the pan-
RAF inhibitor TAK-632 in bothBRAF-mutatedmelanoma cells
and NRAS-mutated melanoma cells with acquired resistance to
BRAF inhibitors [28]. Furthermore, antitumor activity has been
reported in mesothelioma cell lines [29], and tumor growth
suppression has also been seen in patient-derived colorectal
cancer human tumor explants [30], and in mouse xenograft
models of colorectal cancer [27] and lung cancer [31].
Pharmacokinetic data in mouse xenograft models indicate that
plasma concentrations of TAK-733 decrease rapidly 8–16 h
after once-daily oral dosing [25]. Demonstrated pharmacody-
namic effects of MEK inhibition with TAK-733 include de-
creases in phosphorylated ERK (pERK) [26], as seen in both
sensitive and resistant melanoma cell lines and in tumor-bearing
mice; elevated TAK-733 tumor concentrations were shown to
correspond approximately with pERK reductions [25].
Based on these preclinical observations, this first-in-hu-
man, multicenter, open-label, phase I, dose-escalation study
(NCT00948467) was conducted to investigate the safety, tol-
erability, pharmacokinetics, pharmacodynamics, and prelimi-
nary activity of TAK-733 in patients with solid tumors.
Patients and methods
Patients
Patients aged ≥18 years with an Eastern Cooperative
Oncology Group (ECOG) performance status of 0–2; a diag-
nosis of a nonhematologic malignancy for which there was no
standard, curative, or life-prolonging treatment available; and
with radiographically or clinically evaluable tumor (measur-
able disease as defined by the Response Evaluation Criteria
for Solid Tumors [RECIST] was not a requirement during the
dose-escalation stage) were eligible. Patients with ovarian or
prostate cancer with elevated tumor markers (e.g. CA125 or
prostate-specific antigen [PSA]) in the absence of measurable
disease were also eligible. Patients also required adequate he-
matologic, renal, and hepatic function that were defined as:
hemoglobin ≥9 g/dL; an absolute neutrophil count
(ANC) ≥1500/mm3; a platelet count ≥100,000/mm3; a
prothrombin time/international normalized ratio (INR)
or activated partial thromboplastin time ≤ 1.5 times the upper
limit of normal (ULN); calculated creatinine clearance
≥50 mL/min; serum phosphorous or albumin-adjusted serum
calcium ≤ULN; bilirubin ≤1.5 x ULN; and aspartate amino-
transferase (AST), alanine aminotransferase (ALT), or alka-
line phosphatase (ALP) ≤2.5 x ULN (AST, ALT, and ALP
may have been elevated up to 5 x ULN if elevation could be
reasonably ascribed to the presence of metastatic disease to
liver and/or bone).
Patients who had major surgery within 14 days; strong or
moderate CYP3A4 inhibitors/inducers within 14 days; anti-
neoplastic therapy or radiotherapy within 21 days; any inves-
tigational product within 28 days; nitrosoureas or mitomycin
C within 42 days; prior biologic or immunotherapy within
4 weeks; or prior ipilimumab within 4 months of first dose
were not eligible. Patients were also excluded if they had
symptomatic brain metastases; grade ≥ 2 unresolved toxicity
(except alopecia) from previous anticancer treatment; an on-
going or newly diagnosed eye abnormality putting the patient
at risk for retinal vein thrombosis or central serous retinopa-
thy; cardiovascular abnormalities including abnormal left ven-
tricular ejection fraction, electrocardiogram, uncontrolled car-
diovascular condition; or if they were receiving therapeutic
anticoagulation.
Institutional review boards at each of the participating in-
vestigational centers approved the study, which was conduct-
ed in accordance with the ethical principles originating in or
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derived from the Declaration of Helsinki and its amendments
and in accordance with 21 Code of Federal Regulations 50 /
56 / 312. All patients provided written informed consent.
Study design
This was an open-label, multicenter, first-in-human, phase I
dose-escalation study. Patients were enrolled and treated at
five sites in the United States from December 22, 2009, to
April 30, 2013. The primary objectives were to evaluate the
safety profile and determine the dose-limiting toxicities
(DLTs), maximum tolerated dose (MTD), and recommended
phase II dose (RP2D) of TAK-733, and to characterize the
pharmacokinetics of TAK-733. The secondary objective was
to evaluate antitumor activity. Exploratory objectives included
investigating potential pharmacodynamic effects of TAK-733
in peripheral blood mononuclear cells, namely levels of
pERK, and exploring pharmacokinetic/pharmacodynamic
and pharmacokinetic/safety relationships.
Patients received oral TAK-733 once daily on days 1–21 of
28-day treatment cycles. Dose escalation initially proceeded
from a starting dose of 0.2 mg in 100 % increments using a
single-patient cohort design (while allowing enrollment of
additional eligible patients, up to four), until any patient expe-
rienced a DLT or a drug-related grade ≥ 3 non-DLT adverse
event (AE; except creatine kinase elevation) in cycle 1; or any
patient experienced a TAK-733-related grade ≥ 2 AE in cycle
1. Dose escalation then proceeded in ≤40 % increments using
a modified 3 + 3 cohort design. No intra-patient dose escala-
tion was permitted. The MTD was defined as the highest dose
at which cycle 1 DLTs occurred in 0/3 or 1/6 patients. If fewer
than 6 patients had been enrolled, the MTD dose level was
expanded to a total of 6 patients.
DLTs were defined as any of the following considered pos-
sibly related to TAK-733: grade 4 neutropenia lasting ≥7 con-
secutive days or grade ≥ 3 neutropenia with fever/infection;
grade 4 thrombocytopenia lasting ≥7 consecutive days, plate-
let count <10,000/mm3 at any time, or grade ≥ 3 thrombocy-
topenia with clinically significant bleeding; grade 4 anemia;
grade ≥ 3 nausea/emesis despite optimal prophylaxis or
grade ≥ 3 diarrhea despite optimal antidiarrheal therapy; any
other grade ≥ 3 nonhematologic toxicity (except grade ≥ 3
creatine kinase elevation considered not clinically significant);
delay of >2 weeks in initiation of next cycle due to lack of
adequate recovery of TAK-733-related toxicities; the inability
to receive ≥75% of planned doses in a cycle due to TAK-733-
related toxicity; and any other grade ≥ 2 TAK-733-related
toxicities requiring dose reduction or discontinuation.
Following the initial dose-escalation stage, an expansion
stage was planned at the MTD to investigate the safety, phar-
macokinetics, pharmacodynamics, and antitumor activity of
TAK-733 in patients with advanced unresectable melanoma.
However, due to changes in the standard of care for melanoma
treatment during the conduct of this study [32], coupled with a
review of pharmacologic findings and the initial clinical find-
ings on TAK-733 from the present study, a decision was made
to cancel this stage of the study following thorough consider-
ation by the sponsor.
Assessments
AEs were monitored throughout the trial and for 30 days after
the last dose of study medication and were graded using the
National Cancer Institute’s Common Terminology Criteria for
AEs version 3.0. Regular ophthalmologic examination
was included in the safety monitoring. Response was assessed
using the modified RECIST guideline (v1.1) [33]. Blood sam-
ples for determination of TAK-733 plasma concentrations
were obtained at the following time points: pre-dose, and at
0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 h post-dose on days 1 and
21 of cycle 1; pre-dose on days 8 and 15 of cycle 1; 48, 72, 96,
and 120 h post-dose on day 21 of cycle 1; and pre-dose on day
1 of cycle 2. Urine samples were collected over 0–24 h post-
dose on day 21 of cycle 1.
Plasma and urine samples were analyzed for TAK-733
concentrations using validated liquid chromatography–tan-
dem mass spectrometry (LC–MS/MS) methods. The methods
were applicable to the quantitation of TAK-733 within a dy-
namic range of 0.1–200 ng/mL for plasma samples and 5–
10,000 ng/mL for urine samples. Quality controls, analyzed
in duplicate over the validation range, and inter-assay preci-
sion, evaluated at each level in duplicate in six runs, met the
performance and acceptance criteria. Noncompartmental anal-
yses, using WinNonlin version 6.1 or higher (Pharsight, Cary,
NC), in pharmacokinetic-evaluable patients were used to de-
termine plasma and urine pharmacokinetic parameters includ-
ing: Cmax, maximum plasma concentration; Tmax, time to
Cmax; AUC0–τ, area under the plasma concentration–time
curve over the dosing interval; CL/F, apparent clearance; t½,
terminal elimination half-life; accumulation ratio; peak/trough
ratio; and renal clearance.
Blood samples for pharmacodynamic analysis (pERK
levels) were collected at the following time points: pre-dose
and at 0.5, 1, 2, 4, 8, and 24 h post-dose on days 1 and 21 of
cycle 1; pre-dose on days 8 and 15 of cycle 1; 48, 72, 96, and
120 h post-dose on day 21 of cycle 1; and pre-dose on day 1 of
cycle 2. The extent of ERK phosphorylation in peripheral
blood mononuclear cells was determined using an ex vivo
stimulation assay; pERK levels in CD3-positive lymphocytes
were measured by flow cytometry assessing mean fluores-
cence (MEFL) under phorbol myristate acetate (PMA)-stim-
ulated and unstimulated conditions. Mean percent change
from baseline in blood pERK level over time was determined
following single and multiple doses of TAK-733.
Noncompartmental analyses, using WinNonlin version 6.1
or higher (Pharsight, Cary, NC), in pharmacodynamic-
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evaluable patients were used to determine the following phar-
macodynamic parameters for inhibition of ERK phos-
phorylation: maximum observed effect (Emax), time to Emax
(TEmax), area under the effect (inhibition)–time curve over the
dosing interval (AUEC(0-τ)), and average effect over the dos-
ing interval (Eav).
Statistics
The safety population included all patients who received ≥1
dose of TAK-733. The DLT-evaluable population included all
patients who either experienced a DLT during cycle 1 or re-
ceived ≥80 % of scheduled cycle 1 doses without experienc-
ing a DLT. The response-evaluable population included pa-
tients with measurable disease at baseline and ≥1 post-
baseline assessment. The pharmacokinetic-evaluable popula-
tion included patients in the safety population for whom
there were sufficient dosing and sufficient concentration–
time data to reliably estimate pharmacokinetic parameters.
The pharmacodynamic-evaluable population included pa-
tients in the safety population who had sufficient dosing
history and sufficient tumor and/or blood pharmacody-
namic data available.
Results
Patients
Fifty one patients were enrolled and received ≥1 dose of
TAK-733. Patients’ characteristics are summarized in
Table 1. The most common primary diagnoses included
uveal melanoma (24 %), colon cancer (22 %), and cu-
taneous melanoma (10 %). Most (90 %) patients had
received prior antineoplastic therapy, with 71 % having
received three or more prior therapies. Although not an
exclusion criterion for the dose-escalation portion of the
study, no patients were reported to have been previously
treated with inhibitors of the MAPK pathway. Thirty nine
(76 %) patients discontinued treatment due to progressive dis-
ease, 7 (14 %) due to AEs, 2 (4 %) each due to symp-
tomatic deterioration and patient withdrawal, and 1 (2 %) for
non-compliance.
Dose escalation, DLTs, and MTD determination
Fifty one patients received TAK-733 at one of eleven dose
levels: 0.2 mg (n = 1); 0.4 mg (n = 1); 0.8 mg (n = 2);
1.6 mg (n = 2); 3.2 mg (n = 4); 4.4 mg (n = 4); 6 mg
(n = 4); 8.4 mg (n = 9); 11.8 mg (n = 8); 16 mg (n = 9); and
22 mg (n = 7). Forty one patients were included in the DLT-
evaluable population. NoDLTs were observed in patients who
received TAK-733 in the first eight dose cohorts (0.2–8.4 mg).
Subsequently, 4 patients experienced DLTs in cycle 1. In
the 11.8 mg cohort, one of six DLT-evaluable patients had a
DLTof grade 3 dermatitis acneiform on day 21 of cycle 1. The
patient received oral minocycline, topical Neosporin, and top-
ical clindamycin, and TAK-733 was discontinued; the event
resolved approximately 1 week later. In the 16 mg cohort, one
of seven DLT-evaluable patients had a DLTof grade 3 derma-
titis acneiform on day 21. The patient received oral
minocycline, topical clindamycin, and topical hydrocortisone,
and TAK-733 was discontinued; the event was reported as
ongoing at last follow-up. In the 22 mg cohort, one patient
Table 1 Baseline patient demographics and disease characteristics.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell
lung cancer
Characteristic N = 51
Median age, years (range) 58 (24–75)
Male, n (%) 26 (51)
Race, n (%)
White 42 (82)
Black or African American 8 (16)
Not reported 1 (2)
ECOG performance status, n (%)
0 22 (43)
1 29 (57)
Disease primary diagnosis, n (%)
Melanoma uveal 12 (24)
Colon cancer 11 (22)
Melanoma of the skin 5 (10)
Other melanoma* 4 (8)
NSCLC 3 (6)
Anal cancer 2 (4)
Colorectal cancer 2 (4)
Rectal cancer 2 (4)
Other† 10 (20)
Prior therapy, n (%)
Prior surgery or non-radiation procedure 50 (98)
Prior radiation 38 (75)
Prior antineoplastic therapy 46 (90)
1 7 (14)
2 3 (6)
≥ 3 36 (71)
Best response to last prior antineoplastic therapy, n (%)
Partial response 4 (8)
Stable disease 11 (22)
Progressive disease 22 (43)
Unknown 8 (16)
*Melanoma of the scapular, ocular malignant melanoma, ocular melano-
ma, and melanoma: unknown, each n = 1. †Adrenal, bladder, head and
neck, liver, ovarian, and skin cancer, melanoma, sarcoma, unknown high-
grade malignant neoplasm, and unknown primary cancer, each n = 1
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had grade 3 fatigue, pustular rash, and dermatitis acneiform on
day 21 of cycle 1; TAK-733 was discontinued and the events
resolved in approximately 2 weeks. A second patient had
grade 2 dermatitis acneiform and stomatitis on day 12 of cycle
1; the TAK-733 dose was reduced to 16 mg and the events
resolved in 3 and 8 weeks, respectively.
Based on the observed DLTs in cycle 1, the MTD of TAK-
733 was determined to be 16 mg once daily on days 1–21 in
28-day treatment cycles.
TAK-733 exposure and safety profile
Patients received a median of 2 cycles (range 1–11) of TAK-
733; 7 (14%) patients received ≥6 cycles. Themean total dose
of TAK-733 received was 581.66 mg (ranging from 4.2 mg in
the 0.2 mg dose level to 1425.71 mg in the 22.0 mg dose
level), with a mean dose per week of 57.71 mg (ranging from
1.34 to 112.64 mg).
All patients experienced at least one AE of any grade, and
88 % reported drug-related AEs (Table 2). Grade ≥ 3 AEs
were reported in 27 (53%) patients,with drug-related grade≥ 3
AEs reported in 12 (24 %). AEs of any grade reported in at
least 20 % of patients, drug-related AEs reported in at least
10 % of patients, and all drug-related grade ≥ 3 AEs, are listed
in Table 2.
Overall, 34 (67 %) patients experienced any rash AEs. This
included 28 (55 %) with dermatitis acneiform, 3 (6 %) with
rash, 2 (4 %) each with macular rash, maculo-papular rash,
and papular rash, and 1 (2 %) each with exfoliative rash,
erythematous rash, pruritic rash, and pustular rash. Two of
the rash DLTs are shown in Fig. 1. The number of patients
who experienced rash AEs increased with increasing
dose of TAK-733; however, an analysis was conducted indi-
cating no relationship between TAK-733 exposure and skin
AEs (data not shown). No cutaneous squamous cell carcino-
mas were seen.
A total of 7 (14 %) patients experienced ophthalmic AEs
within the eye disorders system organ class, including 1 at
8.4 mg, 2 at 16 mg, and 4 at 22 mg. These included visual
impairment (n = 3), photopsia (n = 2), blurred vision (n = 2),
abnormal sensation in eye, photophobia, periorbital edema,
and retinal edema (each n = 1).
A total of 14 (27 %) patients experienced at least one seri-
ous AE (SAE), including 1 (2 %) who experienced drug-
related SAEs. The only SAEs reported in more than one pa-
tient were progression of metastatic melanoma (n = 3), pul-
monary embolism (n = 2), and anemia (n = 2). One patient
experienced SAEs of hydroureter, hydronephrosis, and pul-
monary embolism that were assessed as possibly related to
TAK-733; the patient had a history of hydroureter and
hydronephrosis at study entry.
Seven (14 %) patients experienced AEs that required TAK-
733 discontinuation; these included: stomatitis in 1 patient at
8.4 mg; dermatitis acneiform in 1 patient at 11.8 mg and 1
patient at 16 mg; pneumonia in 1 patient at 16 mg; seborrheic
dermatitis, swelling face, and fatigue in 1 patient at 16 mg;
fatigue, pustular rash, and dermatitis acneiform (DLT) in 1
patient at 22 mg; and bacteremia in 1 patient at 22 mg. All
AEs were considered related to TAK-733 except for pneumo-
nia and bacteremia.
Five patients died on-study. None of the deaths were con-
sidered related to TAK-733, and all were due to the progres-
sion of the patients’ respective malignancies.
Table 2 Safety profile of TAK-733, including AEs of any grade reported
in at least 20 % of patients, drug-related AEs reported in at least 10 % of
patients, and all drug-related grade ≥ 3 AEs. AE, adverse event; AST,
aspartate aminotransferase; CPK, creatine phosphokinase
AE, n (%) N = 51
Any AE 51 (100)
Common AEs (any grade; ≥20 % of patients)
Dermatitis acneiform 28 (55)
Diarrhea 19 (37)
Fatigue 18 (35)
Peripheral edema 14 (27)
Increased AST 13 (25)
Increased CPK 10 (20)
Decreased appetite 10 (20)
Any drug-related AE 45 (88)
Common drug-related AE (≥10 % of patients)
Dermatitis acneiform 26 (51)
Diarrhea 15 (29)
Increased blood CPK 10 (20)
Fatigue 9 (18)
Stomatitis 9 (18)
Peripheral edema 8 (16)
AST increased 7 (14)
Dry skin 5 (10)
Any grade ≥ 3 AE 27 (53)
Any drug-related grade ≥ 3 AE 12 (24)
Drug-related grade ≥ 3 AEs
Increased blood CPK 5 (10)
Dermatitis acneiform 4 (8)
Stomatitis 1 (2)
Fatigue 1 (2)
Rash pustular 1 (2)
Hypophosphatemia 1 (2)
Pain in extremity 1 (2)
Neuropathy peripheral 1 (2)
Pulmonary embolism 1 (2)
Any serious AE 14 (27)
Any drug-related serious AE 1 (2)
AE resulting in study drug discontinuation 7 (14)
On-study death 5 (10)
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Pharmacokinetics
TAK-733 plasma concentration–time data were available
from all 51 patients who received TAK-733 over the dose
range 0.2–22 mg; plasma concentration–time profiles on day
1 and day 21 of cycle 1 are shown in Fig. 2a and b. Following
oral administration, absorption was fast, with an overall me-
dian Tmax of 3 h (range 0.5–8.1) (Fig. 2a, b, Supplementary
Table S1). Terminal half-life following multiple dosing ranged
from 29 to 50 h over the 11.8–22 mg dose range, peak/trough
ratio ranged from 1.3 to 4.8 (0.2–22 mg dose range), and the
accumulation ratio varied from 0.9 to 9.0 across the 0.2–
22 mg dose range. Dose-proportionality analysis of TAK-
733 steady-state systemic exposure (AUC0–τ) versus dose
showed a point estimate of the slope of 0.8 (95 % CI: 0.63,
0.98), indicating less than a dose-proportional increase over
the TAK-733 dose range of 0.2–22 mg (Fig. 2c).
Urine pharmacokinetic data were available from 16 pa-
tients for estimation of the renal clearance of TAK-733.
Renal clearance ranged from 0.05 to 0.49 L/h, which was
0.5 % to 4.8 % of the apparent oral clearance over the 0.2–
22 mg dose range.
Pharmacodynamics
Data on the pharmacodynamic effects of TAK-733 (inhibition
of ERK phosphorylation in peripheral blood mononuclear
cells, as a biomarker of MEK inhibition) were available for
46 patients. Mean percent changes from baseline in blood
pERK levels following single and multiple TAK-733 doses
are shown in Fig. 3a, b. TEmax ranged from 0.8 to 24 h, with
maximum decrease in pERK at day 21 of 46–97 % (Emax) in
patients receiving doses of 8.4 mg and above. On day 21 of
cycle 1, the duration of pERK decreases appeared relatively
transient at TAK-733 doses of less than 8.4 mg, while at
higher doses target inhibition appeared to be sustained beyond
4 h (Fig. 3a, b). At the MTD of 16 mg, mean Emax was 85 %,
and mean AUEC(0-τ) was 1947 h* % on day 21 of cycle 1,
translating to a mean Eav of 82 % (Table 3). Individual and
mean values of Emax and time-averaged effect by TAK-733
dose at steady state (day 21) are shown in Fig. 3c, d, respec-
tively. No analyses of correlations between pERK decreases
and antitumor effects and no pharmacodynamic analyses at
tumor sites were conducted as part of this study.
Antitumor activity
Among 41 response-evaluable patients, 2 (5 %) patients had
partial responses. One patient (male, age 68 years) with BRAF
L597R cutaneous melanoma, who received TAK-733 at
16 mg, had a partial response that was reported at cycle 4
and maintained until cycle 8 (approximate duration of
4 months). The patient had received three prior lines of ther-
apy with interferon, granulocyte macrophage colony-
stimulating factor (both as adjuvant therapy), and dacarbazine,
as well as prior radiation therapy. A second patient (male, age
68 years) with cutaneous melanoma (mutation status not fea-
sible to determine), who received TAK-733 at 22 mg, had a
partial response at cycle 2 that was maintained until cycle 6
(approximate duration of 4 months). The patient had received
one prior line of therapy with ipilimumab, to which his best
response was progressive disease.
A further 15 (37 %) patients had a best response of stable
disease, and the other 24 (59 %) evaluable patients had pro-
gressive disease. Two patients with melanoma who received
TAK-733 at the 8.4 mg and 22 mg dose levels experienced
stable disease lasting for 6 months or longer.
With a very small sample size, and low rate of responders,
no correlation of mutation profile to response was seen in an
analysis of archival tumor biopsies (data not shown).
Discussion
This was the first-in-human study of TAK-733 in patients with
advanced solid tumors. Our findings showed that the safety
profile of TAK-733 was generally acceptable, with a manage-
able toxicity profile up to a dose of 16 mg QD for 21 days in
28-day cycles, which was determined to be the MTD (n = 9).
Results from pharmacokinetic analyses showed that less than
dose-proportional increases in steady-state exposures of TAK-
733 were observed over the dose range of 0.2–22 mg, and,
Fig. 1 Dose-limiting toxicities (DLTs) of rash seen in patients receiving
TAK-733. a Grade 3 dermatitis acneiform on day 21 of cycle 1 in a
patient receiving TAK-733 11.8 mg – painful rash seen on scalp, face,
and chest (shown in photo). b Grade 2 rash in a patient receiving TAK-
733 22 mg that required dose reduction in cycle 1
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therefore, variability in dose-normalized exposures could not
be assessed. A key finding of importance from the study was
that sustained decreases in blood pERK levels were seen at
higher doses of TAK-733; this anticipated pharmacodynamic
effect of TAK-733 supports the mechanism of action of
MEK1/2 inhibition. Also of note, we showed that two patients
a
b
c
Fig. 2 Pharmacokinetics of
TAK-733 in the pharmacokinetic-
evaluable population. Mean
TAK-733 plasma concentration–
time profiles on a day 1 and b day
21 of cycle 1, and c TAK-733
steady-state systemic exposure
(day 21 AUC0–τ) versus dose
(slope 0.8, 95 % CI: 0.63–0.98)
indicating a less than
dose-proportional relationship
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with cutaneous melanoma, including one with a BRAF
L597R mutation, achieved partial responses that lasted ap-
proximately 4 months, suggesting evidence of preliminary
antitumor activity with TAK-733.
TAK-733 represents one of several MEK1/2 inhibitors be-
ing investigated for the treatment of various cancers [16, 34].
Like the approved agent trametinib, as well as selumetinib
[35] and other investigational MEK1/2 inhibitors, TAK-733
is a non-ATP competitive allosteric inhibitor of the MEK1
andMEK2 BRAF substrates [24]. The findings from the pres-
ent phase I study appear generally consistent with data from
early-phase clinical trials of these other MEK1/2 inhibitors,
which, with the exception of trametinib, have generally dem-
onstrated limited single-agent activity across multiple tumor
types, along with similar DLTs and other toxicities [16, 34].
For example, the DLTs and/or most common drug-related
AEs with TAK-733 in the present phase I study included der-
matitis acneiform, diarrhea, increased blood creatine phospho-
kinase (CPK), fatigue, and stomatitis. These are similar to the
common toxicities reported with other MEK1/2 inhibitors in-
cluding trametinib [36–38], selumetinib [19], RO4987655
[39], and PD-0325901 [40]; trametinib has been reported to
be specifically associated with acneiform eruptions [41].
Similarly, DLTs in other phase I studies of MEK1/2 inhibitors
have included rash, diarrhea, increased blood CPK, and ocular
toxicities with ARRY-424704, refametinib, cobimetinib,
ARRY-438162, and pimasertib [16, 34]. These findings reflect
the general association of dermatologic toxicities with small-
molecule targeted cancer therapies such as kinase inhibitors,
including MEK inhibitors [42, 43].
A notable aspect of the safety profile of TAK-733 was the
limited rate of ophthalmic AEs, and the absence of retinopa-
thies in the present study. Central serous-like retinopathy and
serous retinal detachment, retinal vein occlusion, blurred vi-
sion, transient visual disturbance, and retinal pigment epithe-
lial detachment have all been reported as DLTs with other
MEK1/2 inhibitors in phase I clinical trials [16], with transient
drug-related retinopathies reported with MEK inhibitors in
a
b
c
d
Fig. 3 Pharmacodynamics of TAK-733 in the pharmacodynamic-
evaluable population. Mean percent change from baseline in blood pERK
levels versus time profiles (0–24 h) on a day 1 and b day 21 of cycle 1, and
relationship between dose and (c) maximal pERK decrease (Emax) and (d)
steady-state time-averaged effect (Eav) on day 21 of cycle 1
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patients with metastatic melanoma [37, 44] and MEK inhibi-
tor treatment associated with other ocular adverse events [45].
These ocular toxic effects appear unique toMEK1/2 inhibitors
[16], but did not appear to form a notable component of the
TAK-733 safety profile.
For determination of plasma and urine pharmacokinetic
profile, a validated LC-MS/MS method was employed and
the TAK-733 concentrations were within the dynamic ranges
of the assay (0.1–200 ng/mL for plasma and 5–10,000 ng/mL
for urine). Findings from the analyses of TAK-733 pharmaco-
kinetics in the present study indicated that exposures were
attained that were in excess of those associated with antitumor
activity in preclinical studies. For example, at the 16 mg dose
of TAK-733, the geometric mean steady-state exposure (day
21 AUC0–τ) of 2154.4 h*ng/mL was approximately two-fold
higher than the exposures associated with stasis in the most
sensitive xenograft model treated with single-agent TAK-733
(861–1065 h*ng/mL) [46]. Furthermore, pharmacodynamic
findings also showed that the mean Eav for inhibition of blood
ERK phosphorylation at 16 mg (82 %) exceeded the lower
bound of time-averaged inhibition of ERK phosphorylation
(76–89 %) associated with tumor stasis in xenograft models
treated with single-agent TAK-733 [46]. As was planned in
the cancelled expansion stage, a more informative measure of
the pharmacodynamic effects of TAK-733would have been to
measure its impact on pERK and downstream outcome
markers (e.g. markers of proliferation and apoptosis) in
matched tumor biopsies. Similar pharmacodynamic effects
of target pathway inhibition, i.e. a decrease in pERK levels
in peripheral blood mononuclear cells, malignant cells, and/or
paired tumor biopsies, have been reported with other MEK1/2
inhibitors, including trametinib [37], selumetinib (79 % geo-
metric mean pERK reduction in paired tumor biopsies [19,
22]), ARRY-424704 [47], and RO4987655 [39], and with
the dual Raf/MEK inhibitor RO5126766 [48], although no
correlations with response have been reported.
As with the safety profile and pharmacodynamic effects,
the antitumor activity reported with TAK-733 in the present
study appears consistent with that seen with most other
MEK1/2 inhibitors in early-phase development [16, 34]. The
objective response rate was limited, at 5 %, with responses
including two partial responses in patients with cutaneous
melanoma; additionally, two patients with melanoma
achieved stable disease lasting for 6 months or longer.
Notably, the response in a patient with BRAF L597R mutant
melanoma is consistent with observations with other MEK1/2
inhibitors, including trametinib [36–38], which have shown
activity in BRAF-mutant melanoma. Specifically, trametinib
has been approved by the US FDA for the treatment of BRAF
V600E/K-mutant melanoma, having demonstrated substantial
Table 3 Key TAK-733 pharmacodynamic parameters of decreases in
blood pERK levels following oral administration of TAK-733 at doses of
0.8 to 22 mg in the pharmacodynamic-evaluable population. AUEC(0-τ),
area under the effect (inhibition of ERK phosphorylation)–time curve over
the dosing interval; Eav, average effect (inhibition of ERK phosphorylation)
over the dosing interval; Emax, maximum observed effect of inhibition of
ERK phosphorylation; NR, not reported as n < 2; SD, standard deviation;
TEmax, time to Emax
Dose, mg N Day Emax, % TEmax, h AUEC(0-τ), h*% Eav, %
Mean (SD) Median (range) Mean (SD) Mean (SD)
0.8 2 1 –40.55 (2.5) 3.0 (2–4) –450 (60) –19.3 (2.0)
21 –39.2 (1.1) 3.0 (2–4) NR NR
1.6 2 1 –61.3 (7.0) 4.0 (4–4) –1175 (134) –47 (8.2)
21 –43.0 (21.9) NR –1020 –42.2
3.2 3 1 –41.2 (7.2) 1.1 (1–4) –643 (405) –26.9 (16.9)
21 –66.8 (8.4) NR –785 –31.6
4.4 4 1 –49.2 (3.7) 1.5 (1–2) –542 (492) –22.5 (20.5)
21 –28.0 (6.8) 2.0 (2–4) –164 (447) –6.4 (18.3)
6 3 1 –59.8 (32.7) 4.0 (1–4) –397 (458) –16.5 (18.9)
21 –64.0 (29.6) NR 29 (464) 0.7 (18.7)
8.4 8 1 –64.5 (14.5) 3.0 (1–8) –981 (624) –41.6 (26.5)
21 –63.8 (17.6) 2.1 (1–4) –937 (811) –39.7 (34.2)
11.8 7 1 –61.3 (11.4) 4.1 (4–8) –971 (241) –40.5 (10.0)
21 –79.3 (12.7) 2.2 (2.1–2.3) –1900 –78.1
16 9 1 –77.3 (6.7) 4.0 (2–8) –948 (624) –40.1 (26.3)
21 –84.7 (17.3) 4.6 (4–24) –1947 (125) –82.4 (5.5)
22 7 1 –84.1 (9.0) 7.6 (1–8) –1517 (257) –64.5 (11.3)
21 –82.9 (13.4) 3.1 (1–8) –1615 (288) –66.7 (11.7)
For AUEC(0-τ), Eav, and Emax, the parameters are based on% change from baseline in pERK levels versus time, with inhibition of ERK phosphorylation
being greater the more negative the number
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response rates of approximately 20 % [36, 38] and improved
progression-free survival and overall survival compared to
chemotherapy with dacarbazine or paclitaxel [36] in this pa-
tient population. Subsequently, the combination of MEK1/2
inhibition with trametinib and the BRAF inhibitor dabrafenib
has been FDA-approved based on enhanced responses and
progression-free survival compared to dabrafenib monothera-
py and improved overall survival compared to vemurafenib
monotherapy [49, 50], indicating the importance of dual inhi-
bition of the Ras/Raf/MEK/ERK pathway for improving an-
titumor activity, ameliorating paradoxical activation ofMAPK
signaling and partially overcoming potential resistance to
single-target inhibition, e.g. BRAF inhibition.
In conclusion, the findings of the present phase I study
of TAK-733 have demonstrated a safety profile, pharma-
codynamic effects, and antitumor activity consistent with
other MEK1/2 inhibitors, with key toxicities including der-
matitis acneiform, diarrhea, increased blood CPK, fatigue,
and stomatitis, and limited single-agent antitumor activity,
including a partial response in a patient with BRAF-mutant
melanoma. Given the limited antitumor activity, and in the
context of data with trametinib and the recent changes in
the standards of care in this indication, there are no plans
for the future development of TAK-733 in patients with
melanoma, and there are currently no other ongoing clini-
cal studies of TAK-733.
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